Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200029/S011

TheraSphere

BOSTON SCIENTIFIC CORPORATION · Decision date Feb 10, 2026

FDA DECISIONP200029/S011

What did the FDA approve?

FDA records P200029/S011 as a supplement to PMA P200029, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 10, 2026.

FDA approval order statement

TheraSphere are indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child-Pugh Score A cirrhosis, well-compensated liver function, no macrovascular invasion, and good performance status.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
Radiology
Decision date
Feb 10, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200029/S011
Regulatory pathway
PMA supplement
Product code
NAW
Decision code
APPR
Decision date
Feb 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Microspheres radionuclide.

Product code
NAW
FDA device class
3

For the original device and its historical approval scope, see PMA P200029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200029/S011 received

    Application receipt date recorded by FDA.

  2. P200029/S011 · FDA decision

    Panel Track

  3. P200029/S013 · Related supplement

    TheraSphere Y-90 Glass Microspheres System

  4. P200029/S015 · Related supplement

    TheraSphere Y-90 Glass Microspheres System

Timeline entries are records held by MedtechLedger for P200029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200029

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA approvalMar 17, 2021FDA
TheraSphereP200029/S012
BOSTON SCIENTIFIC CORPORATIONPMA supplementApr 10, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 4, 2026FDA
TheraSphereP200029/S014
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 21, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 13, 2026FDA

Explore the linked device profile

Other records with product code NAW

Product / regulatory recordCompanyPathwayDecision dateSource
Sirtex Medical, Inc.PMA supplementMay 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corporation

Headquarters
Not reported
FDA applicant address
300 Boston Scientific Way, Marborough, MA, 01752

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records